On July 29, 2025, IceCure Medical Ltd. announced the successful expiration and results of its previously announced rights offering. The subscription period, which ended on July 28, 2025, saw the offering approximately two times over-subscribed, demonstrating strong investor confidence. The company expects to receive aggregate gross proceeds of approximately $10.0 million from the offering.
Rights holders validly subscribed for 10,000,000 units at the subscription price of $1.00 per whole unit. An additional 4,627,771 units are expected to be issued pursuant to the over-subscription privilege, indicating significant demand beyond the initial offering. The company expects to deliver the ordinary shares and warrants underlying the purchased units on or about July 30, 2025.
This successful capital raise significantly strengthens IceCure's balance sheet, providing crucial funding for its ongoing regulatory, clinical, and commercial initiatives. The proceeds will be used to repay a $2 million bridge loan from its major shareholder and for general corporate and working capital purposes, supporting the company's strategic growth plans.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.